Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Type 2 cytokines IL-4 and IL-13 increase skin's vulnerability to Staphylococcus aureus, which could be important for treating atopic dermatitis.

IFN-γ and IL-2 are important for T cell activation in hair loss in mice.

Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.

Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.

A specific immune response helps control mite populations on the skin, maintaining healthy hair follicles.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Blocking interferon-gamma might help treat various autoimmune diseases.

Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.

Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

The document concludes that the skin's immune system is complex, involving interactions with hair follicles, nerves, and microbes, and can protect or cause disease, offering targets for new treatments.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Certain proteins, caspases-1 and -11, are important in the early development of skin inflammation in mice.

IL-1 family cytokines are crucial for skin defense and healing, but their imbalance can cause skin diseases.

New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.

taVNS reduces vitiligo symptoms in mice.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

T-regulatory cells are important for skin health and can affect hair growth and reduce skin inflammation.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

New treatments for alopecia areata show promise, but standardized guidelines are needed.

People with alopecia areata are more likely to have anxiety and depression and a lower quality of life.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Red light at 627 nm can safely trigger IL-4 release in skin cells, potentially helping treat inflammatory skin conditions.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Higher IL-17A levels indicate more severe alopecia areata.

Dupilumab can improve both atopic dermatitis and alopecia universalis.

The summit aimed to speed up finding treatments for alopecia areata.